Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Interesting report from 2011
View:
Post by givmeabrake on Nov 02, 2015 12:54pm

Interesting report from 2011

See bottom where it states " Between 2010 and 2020, the market is expected to be led by Urocidin, with forecast sales of $386m.

Article

Research and Markets: Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011


https://www.businesswire.com/news/home/20110413005979/en/Research-Markets-Bladder-Cancer---Global-Drug
Comment by cheetio on Nov 02, 2015 1:04pm
Slighty behind the times..... Apr 2, 2013 Endo Gives Up on Bioniche's Urocidin
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities